Additionally, modulation of CHI3L1 levels through disease-modifying therapies such as natalizumab and fingolimod [8,39], which are known to reduce CHI3L1 levels, could provide another strategy for developing effective treatments for MS. Here, CHI3L1 is linked to myeloid sarcoma.